 Idiopathic Pulmonary Fibrosis
"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Descriptor ID |
D054990
|
| MeSH Number(s) |
C08.381.483.487.500 C08.381.765.500
|
| Concept/Terms |
Idiopathic Pulmonary Fibrosis- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibroses
- Pulmonary Fibroses, Idiopathic
- Familial Idiopathic Pulmonary Fibrosis
- Fibrocystic Pulmonary Dysplasia
- Dysplasia, Fibrocystic Pulmonary
- Dysplasias, Fibrocystic Pulmonary
- Fibrocystic Pulmonary Dysplasias
- Pulmonary Dysplasia, Fibrocystic
- Pulmonary Dysplasias, Fibrocystic
- Fibrosing Alveolitis, Cryptogenic
- Hamman-Rich Disease
- Disease, Hamman-Rich
- Diseases, Hamman-Rich
- Hamman Rich Disease
- Hamman-Rich Diseases
- Interstitial Pneumonitis, Usual
- Interstitial Pneumonitides, Usual
- Pneumonitides, Usual Interstitial
- Pneumonitis, Usual Interstitial
- Usual Interstitial Pneumonitides
- Usual Interstitial Pneumonitis
- Pulmonary Fibrosis, Idiopathic
- Usual Interstitial Pneumonia
- Interstitial Pneumonia, Usual
- Interstitial Pneumonias, Usual
- Usual Interstitial Pneumonias
- Idiopathic Fibrosing Alveolitis, Chronic Form
- Cryptogenic Fibrosing Alveolitis
- Cryptogenic Fibrosing Alveolitides
- Fibrosing Alveolitides, Cryptogenic
- Idiopathic Pulmonary Fibrosis, Familial
|
Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".
This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 | | 2009 | 10 | 2 | 12 | | 2010 | 4 | 0 | 4 | | 2011 | 12 | 1 | 13 | | 2012 | 15 | 1 | 16 | | 2013 | 15 | 1 | 16 | | 2014 | 19 | 2 | 21 | | 2015 | 23 | 3 | 26 | | 2016 | 19 | 3 | 22 | | 2017 | 28 | 1 | 29 | | 2018 | 23 | 2 | 25 | | 2019 | 23 | 1 | 24 | | 2020 | 16 | 1 | 17 | | 2021 | 22 | 0 | 22 | | 2022 | 36 | 0 | 36 | | 2023 | 32 | 0 | 32 | | 2024 | 22 | 4 | 26 | | 2025 | 15 | 1 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
Bousamaki J, Rørbeck EA, Petersen AG, Korntner SH, Pors SE, Redente EF, Oró D, Salinas CG, Olsen RW, Simonsen U, Feigh M, Hansen HH. Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis. Physiol Rep. 2025 Sep; 13(18):e70560.
-
Fortier SM, Redente EF, Peters-Golden M. Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution. Semin Respir Crit Care Med. 2025 Aug; 46(4):298-310.
-
Brazee P, Allen N, Knipe R, Redente EF, Le Saux CJ. Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions. Semin Respir Crit Care Med. 2025 Aug; 46(4):330-346.
-
Tanneberger AE, Blomberg R, Kary AD, Lu A, Riches DWH, Magin CM. Biomaterial-based 3D human lung models replicate pathological characteristics of early pulmonary fibrosis. Acta Biomater. 2025 Sep 15; 204:277-292.
-
Wagner DE, Alsafadi HN, Mitash N, Justet A, Hu Q, Pineda R, Staab-Weijnitz C, Korfei M, Gvazava N, Wannemo K, Onwuka U, Mozurak M, Estrada-Bernal A, Cala-Garcia J, Mutze K, Costa R, Bölükbas D, Stegmayr J, Skronska-Wasek W, Klee S, Ota C, Baarsma HA, Wang J, Sembrat J, Hilgendorff A, Ding J, Günther A, Chambers R, Rosas I, de Langhe S, Kaminski N, Lehmann M, Eickelberg O, Königshoff M. Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models. Nat Commun. 2025 Aug 02; 16(1):7099.
-
Alqalyoobi S, Smith JA, Maddali MV, Pugashetti JV, Newton CA, Kim JS, Linderholm AL, Chen CH, Ma SF, Bose S, Murray S, Adegunsoye A, Strek ME, Garcia CK, Wolters PJ, Martinez FJ, Noth I, Oldham JM. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 Aug; 211(8):1452-1462.
-
Schott CA, Mohning MP, Cooley JC. Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis. Semin Respir Crit Care Med. 2025 Aug; 46(4):347-365.
-
Rodríguez LR, Alysandratos KD, Katzen J, Murthy A, Roque Barboza W, Tomer Y, Bui S, Acín-Pérez R, Petcherski A, Minakin K, Carson P, Iyer S, Chavez K, Cooper CH, Babu A, Weiner AI, Vaughan AE, Arany Z, Shirihai OS, Kotton DN, Beers MF. Impaired AMPK control of alveolar epithelial cell metabolism promotes pulmonary fibrosis. JCI Insight. 2025 Aug 08; 10(15).
-
Goncalves C, Di Napoli M, Schwartz D, Kaplan B. Hidden Markov Models Offer a Powerful Approach for Understanding Gene Regulation Mechanisms Relevant for Organ Transplantation. Transplantation. 2025 08 01; 109(8):1335-1339.
-
Herrera JA, Maslanka M, Blumhagen RZ, Blomberg R, Lwin NY, Brancato J, Cool CD, Huber JP, Kurche JS, Magin CM, Hansen KC, Yang IV, Schwartz DA. The MUC5B promoter variant results in proteomic changes in the nonfibrotic lung. JCI Insight. 2025 Jul 22; 10(14).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|